Close
Novotech
Jabsco PureFlo 21 Single Use

Mission Pharmacal introduces new oral spray for dry mouth

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.

The Hidden Cost of Licensing in Biologic Drug Development

Royalties, milestone payments, and license fees are often treated as the cost of doing business in biopharma. But for early-stage biotech companies building toward an IND, these obligations can quietly reshape financial models, complicate investor conversations, and create downstream deal terms that are difficult to unwind. Here is what founders need to know.
- Advertisement -

US-based pharmaceutical firm Mission Pharmacal has launched a new safe and effective protective oral spray called Aquoral that moistens and lubricates the mouth for up to four hours.

Dry mouth (xerostomia), which affects about 25 million people in the US, refers to a decreased production of saliva, a condition common in older adults and those taking certain prescription medications.

According to the studies, dry mouth affects about 60% of patients taking an anticholinergic medication for treatment of a urologic condition such as overactive bladder (OAB).

Other causes of dry mouth include radiotherapy and systemic diseases such as Sjögren’s syndrome.

Cracked lips, dry tongue, mouth sores and ulcers, mouth infections and dental decay can be caused by dry mouth, whose symptoms include an uncomfortable dry, sticky or burning sensation in the mouth.

Mission Pharmacal marketing director of Urology Division Dan Crawford said dry mouth can significantly decrease patients’ quality of life by making it difficult to chew, swallow, taste, and even speak.

“Most home remedies, such as chewing sugar-free gum or sucking on ice chips, provide only temporary relief from these symptoms,” Crawford said.

“Over-the-counter remedies, which are water-based, don’t last much longer.”

Aquoral uses an Oxidized Glycerol Triesters (OGT) technology, a plant-derived, lipid-based technology designed to function like human saliva, forming a protective barrier on the oral mucosa that lasts up to four hours.

 

Latest stories

Related stories

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.

The Hidden Cost of Licensing in Biologic Drug Development

Royalties, milestone payments, and license fees are often treated as the cost of doing business in biopharma. But for early-stage biotech companies building toward an IND, these obligations can quietly reshape financial models, complicate investor conversations, and create downstream deal terms that are difficult to unwind. Here is what founders need to know.

Early Phase Decisions Drive Faster Drug Development

Strategic early-stage planning and rigorous regulatory readiness serve as the foundation for accelerating pharmaceutical timelines and optimizing long-term R&D efficiency.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »